Bull B S, Huse W M, Brauer F S, Korpman R A
J Thorac Cardiovasc Surg. 1975 May;69(5):685-9.
Because the administration of heparin and protamine according to a set protocol will fail to anticoagulate safely or neutralize appropriately a significant number of patients, a method of monitoring heparin therapy during cardiopulmonary bypass is presented. A dose response curve relating heparin dosage to its effect on the activated coagulation time (ACT) can be determined with sufficient accuracy for clinical purposes from three ACT's. Preparation of such a curve makes it possible to maintain anticoagulation in a safe range during bypass and minimizes the number of monitoring tests of coagulation required. At the conclusion of bypass, this curve can be used to predict the precise amount of protamine needed for neutralization. Freed from the confusing effects of hyperheparinemia or protamine excess, the physician can diagnose and treat postoperative bleeding problems much more readily.
由于按照既定方案使用肝素和鱼精蛋白会导致相当数量的患者无法安全抗凝或无法得到适当中和,本文提出一种在体外循环期间监测肝素治疗的方法。从三次活化凝血时间(ACT)测定结果中,能够以足够的精度确定肝素剂量与其对ACT影响之间的剂量反应曲线,以满足临床需求。绘制这样一条曲线可以在体外循环期间将抗凝维持在安全范围内,并减少所需的凝血监测测试次数。在体外循环结束时,该曲线可用于预测中和所需鱼精蛋白的精确用量。摆脱了高肝素血症或鱼精蛋白过量的干扰影响后,医生能够更轻松地诊断和治疗术后出血问题。